Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $80.2 million.

  • Anika Therapeutics' Cash & Current Investments fell 1162.63% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year decrease of 1162.63%. This contributed to the annual value of $79.2 million for FY2024, which is 1669.51% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Cash & Current Investments is $80.2 million, which was down 1162.63% from $77.1 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash & Current Investments registered a high of $124.2 million during Q4 2021, and its lowest value of $75.4 million during Q1 2025.
  • In the last 5 years, Anika Therapeutics' Cash & Current Investments had a median value of $97.2 million in 2021 and averaged $100.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 3268.62% in 2021, then surged by 3404.08% in 2022.
  • Over the past 5 years, Anika Therapeutics' Cash & Current Investments (Quarter) stood at $124.2 million in 2021, then dropped by 2.64% to $121.0 million in 2022, then fell by 21.38% to $95.1 million in 2023, then dropped by 16.7% to $79.2 million in 2024, then rose by 1.2% to $80.2 million in 2025.
  • Its last three reported values are $80.2 million in Q3 2025, $77.1 million for Q2 2025, and $75.4 million during Q1 2025.